Next, we assessed the ability of AFM28 to induce ADCC by allogeneic healthy NK cells against LSPCs that were phenotypically defined as CD34+ CD38− CD117+ cell population (means of 0.3% and 6.8% in patient AML and HR-MDS BMMCs, respectively) (Fig. 3A and Supplementary Fig. 2A–D). This evidence concerns the gene KIT and acute myeloid leukemia.